Uso dos biomarcadores plasmáticos na otimização do diagnóstico precoce do Alzheimer
Article Sidebar
Main Article Content
Abstract
Objetivo: Avaliar a eficácia do uso de biomarcadores plasmáticos no diagnóstico precoce do Alzheimer. Metodologia: O presente estudo trata-se de uma revisão integrativa da literatura, em que foram realizadas buscas, no período de outubro de 2019, por publicações nas base de dados U.S. National Library of Medicine and the National Institutes Health (PubMed) e na Scientific Electronic Library Online (SciELO) nos últimos 5 anos. Os descritores empregados para a seleção dos estudos, obtidos junto aos Descritores em Ciências da Saúde (DeCS), foram: Alzheimer AND Biomarcadores plasmáticos AND Diagnóstico precoce. Resultados: Foram selecionados 19 artigos após aplicados os critérios de inclusão e exclusão. Após a categorização e análise das publicações, foi identificado que 100% (n=19) dos artigos foram publicados em inglês, 36,8% (n=7) foram publicados em 2018 e 42,10% (n=8) abordavam a temática dos biomarcadores proteicos. Conclusão: Os biomarcadores plasmáticos são eficazes no diagnóstico precoce do Alzheimer, possibilitando um tratamento antecipado e mais eficiente no retardo da progressão dos sintomas. O uso combinado dos biomarcadores pode representar a melhor abordagem de rastreio, uma vez que teriam uma alta acurácia.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
• The author (s) warrant that the contribution is original and unpublished and that it is not in the process of being evaluated in other journal (s);
• The journal is not responsible for the opinions, ideas and concepts issued in the texts, as they are the sole responsibility of the author (s);
• Publishers have the right to make textual adjustments and to adapt the article to the rules of publication.
Authors retain the copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution License, which allows the sharing of work with acknowledgment of authorship and initial publication in this journal.
Authors are authorized to take additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (eg publish in institutional repository or as book chapter), with acknowledgment of authorship and initial publication in this journal.
Authors are allowed and encouraged to publish and distribute their work online (eg in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and citation of the published work (See The Effect of Free Access) at http://opcit.eprints.org/oacitation-biblio.html
References
BLENNOW, K. A review of fluid biomarkers for alzheimer’s disease: switching from csf to blood. Neurology Therapy, v. 6, p.15-24, 2017.
BLENNOW, K.; ZETTERBERG, H. The past and the future of alzheimer’s disease flud biomarkers. Journal of Alzheimer´s Desease, v. 62, p.1125-1140, 2018.
CLEMENTE, C.E.T.; PINTO, R.A.S.R. Revisão e atualização dos biomarcadores no líquor para doença de alzheimer. Revista Brasileira de Neurologia e Psiquiatria, v. 21, p.1-18, 2017.
DORNINGER, F.; MOSER, A. B.; KOU, J.; WIESINGER, C.; FORSS-PETTER, S.; GLEISS, A.; BERGER, J. Alterations in the plasma levels of specific choline phospholipids in alzheimer’s disease mimic accelerated Aging. Journal of Alzheimer´s Desease,v. 62, p.841-854, 2018.
GARYFALLOU, G. Z.; KETEBU, O.; ŞAHIN, S.; MUKAETOVA-LADINSKA, E. B.; CATT, M.; YU, E. H. Electrochemical detection of plasma immunoglobulin as a biomarker for alzheimer’s disease. Sensors, v. 17, p. 2464-2477, 2017.
GOETZL, E. J.; BOXER, A.; SCHWARTZ, J. B.; ABNER, E. L.; PETERSEN, R. C.; MILLER, B. L.; KAPOGIANNIS, D. Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology, v. 85, p.40-47, 2015.
GOETZL, E. J.; KAPOGIANNIS, D.; SCHWARTZ, J. B.; LOBACH, I. V.; GOETZL, L.; ABNER, E. L.; MILLER, B. L. Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s disease. The Journal of the Federation of American Societies for Experimental Biology, v. 30, p.4141-4148, 2016.
GUAN, C.; DANG, R.; CUI, Y.; LIU, L.; CHEN, X.; WANG, X.; WANG, D. Characterization of plasma metal profiles in alzheimer’s disease using multivariate statistical analysis. Plos One, v. 12, p.1-18, 2017.
HADAR, A.; GURWITZ, D. Peripheral transcriptomic biomarkers for early detection of sporadic Alzheimer disease? Dialogues in Clinical Neurosciense, v. 20, p.293-300, 2018.
HAIGHT, T.; BRYAN, R. N.; MEIRELLES, O.; TRACY, R., FORNAGE, M.; RICHARD, M.; LAUNER, L. J. Associations of plasma clusterin and alzheimer’s disease-related MRI markers in adults at mid-life: the cardia brain MRI sub-study. Plos One, v. 13, p.1-29, 2018.
HAMPEL, H.; PRVULOVIC, D.; TEIPEL, S.; JESSEN, F.; LUCKHAUS, C.; FRÖLICH, L. The future of alzheimer´s disease: the next 10 years. Progress in Neurobiology, v. 95, p.718-728, 2011.
KIDDLE, S. J.; STEVES, C. J.; MEHTA, M.; SIMMONS, A., XU, X. Plasma protein biomarkers of Alzheimer’s disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumes. Translational Psychiatry, v. 5, p.1-17, 2015.
KUMAR, S.; REDDY, P.H. Are circulating microRNAs peripheral biomarkers for alzheimer’s disease? Biochim Biophys Acta, v. 1862, p.1617-1627, 2016.
LAWRENCE, E.; VEGVARI, C.; OWER, A.; HADJICHRYSANTHOU, C.; DE WOLF, F.; ANDERSON, R. M. A Systematic review of longitudinal studies which measure alzheimer’s disease biomarkers. Journal of Alzheimer´s Desease, v. 59, p.1359-1379, 2017.
LEWCZUK, P.; ERMANN, N.; ANDREASSON, U.; SCHULTHEIS, C.; PODHORNA, J.; SPITZER, P.; ZETTERBERG, H. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease. Alzheimers Reseach & Therapy, v. 10, p.1-27, 2018.
MCINTYRE, J. A.; RAMSEY, C. J.; GITTER, B. D.; SAYKIN, A. J.; WAGENKNECHT, D. R.; HYSLOP, P. Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer’s disease. Autoimmunity, v. 48, p.344-351, 2015.
MUSHTAQ, G.; H GREIG, N.; ANWAR, F.; A ZAMZAMI, M.; CHOUDHRY, H.; M SHAIK, M.; A, KAMAL, M. MiRNAs as circulating biomarkers for alzheimer’s disease and parkinson’s disease. Journal of Medicinal Chemistry, v. 12, p.217-225, 2016.
MOLINUEVO, J. L.; AYTON, S.; BATRLA, R.; BEDNAR, M. M.; BITTNER, T.; CUMMINGS, J.; BLENNOW, K. Current state of alzheimer’s fuid biomarkers. Acta Neuropathologica, v. 136, p.821-853, 2018.
MOLINUEVO, J. L.; AYTON, S.; BATRLA, R.; BEDNAR, M; M., BITTNER, T.; CUMMINGS, J.; BLENNOW, K. Amyloid blood biomarker detects alzheimer’s disease. Embo Molecular Medicine, v. 10, p.1-24, 2018.
NAGARAJ, S.; LASKOWSKA-KASZUB, K.; DĘBSKI, K. J.; WOJSIAT, J.; DĄBROWSKI, M.; GABRYELEWICZ, T.; WOJDA, U. Profile of 6 microRNA in blood plasma distinguish early stage alzheimer’s disease patients from non-demented subjects. Oncotarget, v. 8, p.16122-16143, 2017.
RUAN, Q.; D'ONOFRIO, G.; SANCARLO, D.; GRECO, A.; YU, Z. Potential fluid biomarkers for pathological brain changes in alzheimer’s disease: implication for the screening of cognitive frailty. Molecular Medicine Reports, v. 14, p.3184-3198, 2016.
DA SILVA, L. R.; VIANNA, C. M.; MOSEGUI, G. B.; PEREGRINO, A. A.; MARINHO, V.; LAKS, J. Cost-effectiveness analysis of the treatment of mild and moderate alzheimer’s disease in brazil. Brazilian Journal of Psychiatry, v. 41, p. 218-224, 2019.
SOUZA, M.T.S.; SILVA, M.D.S.; CARVALHO, R.C. Integrative review: what is it? How to do it? Einstein (São Paulo), v. 8, p.102-106, 2010.
SWARBRICK, S.; WRAGG, N.; GHOSH, S.; STOLZING, A. Systematic review of miRNA as biomarkers in alzheimer’s disease. Molecular Neurobiology, v. 56, p.6156-6167, 2019.
VERBERK, I. M.; SLOT, R. E.; VERFAILLIE, S. C.; HEIJST, H.; PRINS, N. D.; VAN BERCKEL, B. N.; VAN DER FLIER, W. M. Plasma amyloid as prescreener for the earliest alzheimer pathological changes. Annals of neurology, v. 84, p.648-658, 2018.
WELLER, J.; BUDSON, A. Current understanding of alzheimer’s disease diagnosis and treatment. F1000 Research, v. 7, p.1-9, 2018.
YAO, F.; ZHANG, K.; ZHANG, Y.; GUO, Y.; LI, A.; XIAO, S.; NI, J. Identification of blood biomarkers for alzheimer’s disease through computational prediction and experimental validation. Frontiers in Neurology, v. 9, p.1-31, 2019.
ZETTERBERG, H.; BURNHAM, S.C. Blood-based molecular biomarkers for alzheimer’s disease. Molecular Brain, v. 12, p.1-16, 2019.